GlassScriptPhysician profile
Jeffrey S Lambert
NPI 1578762134
$1,059.30
in general payments reported to CMS, 2019-2025
14 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.88 · 2022: $263 · 2023: $214 · 2024: $285 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $266.90 | 2022-2025 | Shingrix, Arexvy |
| Pfizer INC. | $153.16 | 2019-2025 | |
| Amgen INC. | $150.46 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $105.89 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $86.75 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $63.23 | 2022-2025 | |
| Abbvie INC. | $62.31 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $44.55 | 2024 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $35.40 | 2025 | Libtayo |
| Viiv Healthcare Company | $23.76 | 2022 | |
| Boston Scientific Corporation | $22.09 | 2023 | Watchman Access System |
| Idorsia Pharmaceuticals US INC | $18.30 | 2023 | Quviviq |
| Davol INC. | $13.77 | 2024 | Phasix Mesh |
| Astrazeneca Pharmaceuticals LP | $12.73 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.